Risks of its use include an increase in arterial thrombosis.

In those with a history of arterial thrombosis, non-hormonal birth control should be used.

G20120A can thus contribute to a state of hypercoagulability, but not particularly with arterial thrombosis.

Arterial thrombosis is the formation of a thrombus within an artery.

This is useful in the management of arterial thrombosis and prevention of adverse cardiovascular events.

Blood clots in the arteries (acute arterial thrombosis).

In most cases, arterial thrombosis follows rupture of atheroma, and is therefore referred to as atherothrombosis.

Treatment of established arterial thrombosis includes the use of antiplatelet drugs and thrombolytic therapy.

The mechanism behind arterial thrombosis, such as with heart attacks, is more established than the steps that cause venous thrombosis.

Arterial thrombosis or embolism has a dismal prognosis, but is occasionally treated successfully with thrombolysis.

The PF4-heparin complex can activate platelets and may cause venous and arterial thrombosis.

It also covers arterial thrombosis and embolism; vasculitides; and vasospastic disorders.

Examples of arterial thrombosis are stroke, myocardial infarction ("heart attack"), and acute leg ischemia.

Central retinal vein and/or central retinal arterial thrombosis.

Whether thrombophilia also increases the risk of arterial thrombosis (which is the underlying cause of heart attacks and strokes) is less well established.

Individuals with arterial thrombosis or embolism often develop collateral circulation to compensate for the loss of arterial flow.

The major cause of acute limb ischaemia is arterial thrombosis (85%), while embolic occlusion makes up 15% of causes.

Antiplatelet drugs alter the platelet activation at the site of vascular damage crucial to the development of arterial thrombosis.

APD791, Phase I, indication: arterial thrombosis.

With arterial thrombosis, blood vessel wall damage is required, as it initiates coagulation, but clotting in the veins mostly occurs without any such damage.

Though it is named for associated low platelet counts, HIT is strongly associated with risk of venous and arterial thrombosis.

Arterial thrombosis can embolize and is a major cause of arterial embolism, potentially causing infarction of almost any organ in the body.

There are two distinct forms of thrombosis, venous thrombosis and arterial thrombosis, each of which can be presented by several subtypes.

Taken together, the studies suggest that polymorphisms predisposing to arterial thrombosis may differ from polymorphisms predisposing to deep vein thrombosis.

One mutation of especial interest involves de coagulation factor XIII and protects against the occurrence of arterial thrombosis.